Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2010: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Research Abstract |
Considering the safety to clinical application of gene therapy for secondary hyperparathyroidism (2HPT), we attempted the establishment of the RNA interference system in order to prevent damaging patient's genomes. Expression of miRNA for human parathyroid hormone (hPTH) was controlled with tetracycline inducible promotor in modified HEK293 cells which express hPTH constitutively. The cells were transplanted into nudemice, and secretion of hPTH into serum was confirmed. As the decrease of hPTH concentration in serum by feeding doxycycline was shown, the validity of this system was checked. In parallel to this, the survey of new target genes applied to this system found c-myc and p27Kip1, genes related with apoptosis of parathyroid cells.
|